All In Biotech

Drug Trial Radar · NCT06275620

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa

Last checked: Nov 20, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 14, 2023

Primary completion

Nov 2025

Study completion Dec 2029

Sponsor

Lead sponsor
Beacon TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.

Conditions

  • X-Linked Retinitis Pigmentosa

Interventions

  • AGTC-501 (high dose and standard corticosteroid regimen)Biological

    Adeno-associated virus vector expressing a human RPGR gene

  • AGTC-501 (low dose and standard corticosteroid regimen)Biological

    Adeno-associated virus vector expressing a human RPGR gene

  • AGTC-501 (high dose and modified corticosteroid regimen)Biological

    Adeno-associated virus vector expressing a human RPGR gene

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary safety outcome is the number of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs).Time frame: Day 0 - Month 12
  2. The primary safety outcome is the proportion of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs).Time frame: Day 0 - Month 12

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Jacksonville, Florida

  • Bascom Palmer Eye Institute

    Miami, Florida

  • Boston Children's Hospital

    Boston, Massachusetts

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Casey Eye Institute

    Portland, Oregon

  • Retina Foundation of the Southwest

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.